These data are typically included in preoperative nomograms in patients without distant metastatic disease on conventional imaging (i.e., bone scintigraphy and computed tomography (CT)) and, more recently, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) [2, 3]. This evidence concerns the gene FOLH1 and metastatic neoplasm.